Insights & Resources

Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.

As risk evolves, life science companies must adapt valuation methods. Learn to better align risk, value and strategy in your decision-making process.

The National Association of Manufacturers (NAM) Q2 survey reveals emerging risks. Explore what this means for your governance and risk strategy.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Discover how outsourcing in pharmaceutical manufacturing enhances quality, ensures compliance and mitigates risks in a rapidly evolving industry.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

New York’s business interruption law introduced new stand-alone coverage opportunities, providing businesses options for tailored protection.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.